Bellevue Group AG Files Exit Amendment (13G/A) for Celldex Therapeutics, Inc. Holding

On May 15, 2026, Bellevue Group AG and its wholly-owned subsidiary, Bellevue Asset Management AG (BAM AG), filed an amended Schedule 13G (Amendment No. 1) regarding their holdings in Celldex Therapeutics, Inc. (CLDX). The filing reveals that as of March 31, 2026, the reporting persons beneficially own 1,200,000 shares of common stock, representing a 1.5% ownership stake in the company. This ownership is based on 78,492,072 shares outstanding. Notably, this filing serves as an exit filing for Bellevue Group AG and BAM AG, as their combined ownership has fallen below the 5% threshold required for continued reporting under Schedule 13G. The shares are held with shared voting and dispositive power. The reporting entities are based in Zurich, Switzerland, and acquired the securities in the ordinary course of business without the intent to influence or change control of the issuer.